Literature DB >> 26988652

Transforming Growth Factor-β Is an Upstream Regulator of Mammalian Target of Rapamycin Complex 2-Dependent Bladder Cancer Cell Migration and Invasion.

Sounak Gupta1, Andrew M Hau1, Hikmat A Al-Ahmadie2, Jyoti Harwalkar3, Aaron C Shoskes3, Paul Elson4, Jordan R Beach5, George S Hussey6, William P Schiemann7, Thomas T Egelhoff5, Philip H Howe6, Donna E Hansel8.   

Abstract

Our prior work identified the mammalian target of rapamycin complex 2 (mTORC2) as a key regulator of bladder cancer cell migration and invasion, although upstream growth factor mediators of this pathway in bladder cancer have not been well delineated. We tested whether transforming growth factor (TGF)-β, which can function as a promotility factor in bladder cancer cells, could regulate mTORC2-dependent bladder cancer cell motility and invasion. In human bladder cancers, the highest levels of phosphorylated SMAD2, a TGF-β signaling intermediate, were present in high-grade invasive bladder cancers and associated with more frequent recurrence and decreased disease-specific survival. Increased expression of TGF-β isoforms, receptors, and signaling components was detected in invasive high-grade bladder cancer cells that expressed Vimentin and lacked E-cadherin. Application of TGF-β induced phosphorylation of the Ser473 residue of AKT, a selective target of mTORC2, in a SMAD2- and SMAD4-independent manner and increased bladder cancer cell migration in a modified scratch wound assay and invasion through Matrigel. Inhibition of TGF-β receptor I using SB431542 ablated TGF-β-induced migration and invasion. A similar effect was seen when Rictor, a key mTORC2 component, was selectively silenced. Our results suggest that TGF-β can induce bladder cancer cell invasion via mTORC2 signaling, which may be applicable in most bladder cancers.
Copyright © 2016. Published by Elsevier Inc.

Entities:  

Mesh:

Substances:

Year:  2016        PMID: 26988652      PMCID: PMC4861762          DOI: 10.1016/j.ajpath.2016.01.008

Source DB:  PubMed          Journal:  Am J Pathol        ISSN: 0002-9440            Impact factor:   4.307


  38 in total

Review 1.  TGF-beta and immune cells: an important regulatory axis in the tumor microenvironment and progression.

Authors:  Li Yang; Yanli Pang; Harold L Moses
Journal:  Trends Immunol       Date:  2010-06-01       Impact factor: 16.687

Review 2.  TGF-beta and epithelial-to-mesenchymal transitions.

Authors:  Jiri Zavadil; Erwin P Böttinger
Journal:  Oncogene       Date:  2005-08-29       Impact factor: 9.867

Review 3.  Snail, Zeb and bHLH factors in tumour progression: an alliance against the epithelial phenotype?

Authors:  Héctor Peinado; David Olmeda; Amparo Cano
Journal:  Nat Rev Cancer       Date:  2007-05-17       Impact factor: 60.716

4.  Integrative analysis of complex cancer genomics and clinical profiles using the cBioPortal.

Authors:  Jianjiong Gao; Bülent Arman Aksoy; Ugur Dogrusoz; Gideon Dresdner; Benjamin Gross; S Onur Sumer; Yichao Sun; Anders Jacobsen; Rileen Sinha; Erik Larsson; Ethan Cerami; Chris Sander; Nikolaus Schultz
Journal:  Sci Signal       Date:  2013-04-02       Impact factor: 8.192

5.  Mammalian target of rapamycin (mTOR) regulates cellular proliferation and tumor growth in urothelial carcinoma.

Authors:  Donna E Hansel; Eric Platt; Mohammed Orloff; Jyoti Harwalker; Swathi Sethu; Jessica L Hicks; Angelo De Marzo; Roxanne E Steinle; Eric D Hsi; Dan Theodorescu; Christina B Ching; Charis Eng
Journal:  Am J Pathol       Date:  2010-04-15       Impact factor: 4.307

Review 6.  TGFβ signalling in context.

Authors:  Joan Massagué
Journal:  Nat Rev Mol Cell Biol       Date:  2012-09-20       Impact factor: 94.444

7.  Inhibition of TGF-beta receptor I by siRNA suppresses the motility and invasiveness of T24 bladder cancer cells via modulation of integrins and matrix metalloproteinase.

Authors:  Yubing Li; Kai Yang; Qiqi Mao; Xiangyi Zheng; Debo Kong; Liping Xie
Journal:  Int Urol Nephrol       Date:  2009-08-08       Impact factor: 2.370

8.  TGF-β effects on prostate cancer cell migration and invasion are mediated by PGE2 through activation of PI3K/AKT/mTOR pathway.

Authors:  Baohan T Vo; Derrick Morton; Shravan Komaragiri; Ana C Millena; Chelesie Leath; Shafiq A Khan
Journal:  Endocrinology       Date:  2013-03-20       Impact factor: 4.736

9.  Critical role of a survivin/TGF-β/mTORC1 axis in IGF-I-mediated growth of prostate epithelial cells.

Authors:  Kyung Song; Eswar Shankar; Jiayi Yang; Kara L Bane; Reema Wahdan-Alaswad; David Danielpour
Journal:  PLoS One       Date:  2013-05-01       Impact factor: 3.240

10.  Genetic variations in the transforming growth factor beta pathway as predictors of bladder cancer risk.

Authors:  Hua Wei; Ashish M Kamat; Saad Aldousari; Yuanqing Ye; Maosheng Huang; Colin P Dinney; Xifeng Wu
Journal:  PLoS One       Date:  2012-12-12       Impact factor: 3.240

View more
  15 in total

1.  Elucidating the role of Agl in bladder carcinogenesis by generation and characterization of genetically engineered mice.

Authors:  Joseph L Sottnik; Vandana Mallaredy; Ana Chauca-Diaz; Carolyn Ritterson Lew; Charles Owens; Garrett M Dancik; Serena Pagliarani; Sabrina Lucchiari; Maurizio Moggio; Michela Ripolone; Giacomo P Comi; Henry F Frierson; David Clouthier; Dan Theodorescu
Journal:  Carcinogenesis       Date:  2019-03-12       Impact factor: 4.944

2.  IFITM3/STAT3 axis promotes glioma cells invasion and is modulated by TGF-β.

Authors:  Hongliang Wang; Feng Tang; Erbao Bian; Yile Zhang; Xinghu Ji; Zhihao Yang; Bing Zhao
Journal:  Mol Biol Rep       Date:  2019-10-21       Impact factor: 2.316

3.  Anti-PD-L1/TGFβR2 (M7824) fusion protein induces immunogenic modulation of human urothelial carcinoma cell lines, rendering them more susceptible to immune-mediated recognition and lysis.

Authors:  Italia Grenga; Renee N Donahue; Morgan L Gargulak; Lauren M Lepone; Mario Roselli; Marijo Bilusic; Jeffrey Schlom
Journal:  Urol Oncol       Date:  2017-11-02       Impact factor: 3.498

4.  Targeting mTORC2 component rictor inhibits cell proliferation and promotes apoptosis in gastric cancer.

Authors:  Yu-Hai Bian; Jia Xu; Wen-Yi Zhao; Zi-Zhen Zhang; Lin Tu; Hui Cao; Zhi-Gang Zhang
Journal:  Am J Transl Res       Date:  2017-09-15       Impact factor: 4.060

5.  Evaluation of zinc finger E-box binding homeobox 1 and transforming growth factor-beta2 expression in bladder cancer tissue in comparison with healthy adjacent tissue.

Authors:  Ali Mahdavinezhad; Reza Yadegarazari; Seyed Habibollah Mousavi-Bahar; Jalal Poorolajal; Mohammad Jafari; Mohammad Ali Amirzargar; Hosein Effatpanah; Massoud Saidijam
Journal:  Investig Clin Urol       Date:  2017-02-15

6.  Collagen Type VI Alpha 3 Chain Promotes Epithelial-Mesenchymal Transition in Bladder Cancer Cells via Transforming Growth Factor β (TGF-β)/Smad Pathway.

Authors:  Yan Huang; Gang Li; Kai Wang; Zhongyi Mu; Qingpeng Xie; Hongchen Qu; Hang Lv; Bin Hu
Journal:  Med Sci Monit       Date:  2018-08-01

Review 7.  TGF-β and microRNA Interplay in Genitourinary Cancers.

Authors:  Joanna Boguslawska; Piotr Kryst; Slawomir Poletajew; Agnieszka Piekielko-Witkowska
Journal:  Cells       Date:  2019-12-12       Impact factor: 6.600

8.  Effects of increased Kindlin-2 expression in bladder cancer stromal fibroblasts.

Authors:  Jitao Wu; Cuicui Yu; Li Cai; Youyi Lu; Lei Jiang; Chu Liu; Yongwei Li; Fan Feng; Zhenli Gao; Zhe Zhu; Shengqiang Yu; Hejia Yuan; Yuanshan Cui
Journal:  Oncotarget       Date:  2017-04-10

9.  RICTOR amplification identifies a subgroup in small cell lung cancer and predicts response to drugs targeting mTOR.

Authors:  Nneha Sakre; Gary Wildey; Mohadese Behtaj; Adam Kresak; Michael Yang; Pingfu Fu; Afshin Dowlati
Journal:  Oncotarget       Date:  2017-01-24

10.  HDAC5 Expression in Urothelial Carcinoma Cell Lines Inhibits Long-Term Proliferation but Can Promote Epithelial-to-Mesenchymal Transition.

Authors:  Ananda Ayyappan Jaguva Vasudevan; Michèle J Hoffmann; Michael L C Beck; Gereon Poschmann; Patrick Petzsch; Constanze Wiek; Kai Stühler; Karl Köhrer; Wolfgang A Schulz; Günter Niegisch
Journal:  Int J Mol Sci       Date:  2019-04-30       Impact factor: 5.923

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.